EU-Wide OTC Approvals Highlight The Drawbacks Of National Processes
This article was originally published in The Tan Sheet
Executive Summary
National switches comprise the majority of OTC approvals in Europe, and likely will until the European Union opens restrictions on which drugs can use its nascent centralized switch process
You may also be interested in...
Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec
European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.
Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec
European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.
GSK Urges Regulatory Changes To Pull EU Market From Doldrums
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.